ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.

Recs

0
Player Avatar toaoyoda (20.85) Submitted: 2/10/2012 3:12:53 PM : Outperform Start Price: $8.32 ISIS Score: +19.08

This biotech has been "promising" for two decades but its platform seems finally at a critical mass with several drugs poised ( in collaboration with larger, pharma companies ) to enter the market, especially in areas not well-served by other drugs. Intrinsically, the platform should entail fewer side effects than more traditional drugs.

Featured Broker Partners


Advertisement